

We improve people's health and lives through innovation that makes healing possible. By advancing rigorous science and increasing access to evidence-based regenerative technologies, we elevate the standard of care.

MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.

As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions.

MARKET SIZE:

US Advanced Wound Care⁶

\$1.1B

US Surgical Recovery⁷

\$0.9B

Japan⁸

\$0.5B

COMMERCIAL PRODUCTS


MIMEDX pioneered the placental allograft market and has over 10 years of clinical, scientific, and industry experience in utilizing amniotic tissue as a platform for regenerative medicine. Today, we are a leading supplier of placental allografts used in multiple sectors of healthcare, including wound care, burns, and surgical applications.

ADVANCED WOUND CARE

EPIFIX[®]




EPIFIX[®]
MESH



EPICORD[®]



EPICORD[®]
EXPANDABLE



SURGICAL RECOVERY

Our next generation of product developments include AMNIOEFFECT™, a thicker, tri-layer placental allograft intended for surgical applications, and AXIOFILL™, an extracellular matrix particulate derived from placental disc and intended for deeper, tunneling wounds.

AMNIOFIX[®]



AMNIOCORD[®]



AMNIOEFFECT™



AXIOFILL™
ECM PARTICULATE



KEY FACTS

Headquarters: Marietta, Georgia

Ticker: MDXG

Founded: 2008

Employees: 811 (at 12/31/21)

TTM¹ Net Sales: \$256.3M

TTM¹ Growth in Wound Care & Surgical Recovery business: 12.7%

TTM¹ Gross Margin: 83.4%

TTM¹ Adjusted EBITDA²: \$8.0M

Cash (at 6/30/22): \$72.5M

US reimbursement coverage:
300M+ lives

US population with diabetes³: 30M

US chronic wounds⁴: 2.9M

Medicare cost of diabetic-related ulcers per year⁵: ~\$20B

Allografts supplied for patients:
2M+

#1 amniotic skin substitute⁴

50+ scientific and clinical publications

MIMEDX GROUP, INC.

1775 West Oak Commons Ct. NE
Marietta, GA 30062
(770) 651-9100
www.mimedx.com

CONTACT INVESTOR RELATIONS

(770) 651-9066
investorrelations@mimedx.com




MUSCULOSKELETAL PIPELINE

MIMEDX is leading clinical trials to demonstrate the clinical effectiveness of our placental biologic injectable, micronized dehydrated human amnion chorion membrane (mdHACM) in Knee Osteoarthritis (KOA), including its potential to moderate the progression of KOA. Our registrational trials are planned for initiation in late 2022.

KOA is an area of significant unmet need and represents a potential blockbuster drug opportunity. There are 19 million patients with KOA in the US,⁹ 12 million of whom are targets for hyaluronic acid injections.¹⁰

GROWTH STRATEGY¹¹

Transforming medicine in large and high-growth markets with significant unmet needs.



2022 ANTICIPATED MILESTONES

- 01 Achieve annual sales growth of 11% to 14% in continuing portfolio of products
- 02 Launch two new, organic products in the U.S.: AMNIOEFFECT™ and AXIOFILL™, facilitating expansion into additional areas of significant unmet clinical need
- 03 Expand the Company's international footprint with the initial launch of EPIFIX® in Japan
- 04 Commence registrational KOA clinical trial program
- 05 Implement rigorous Current Good Manufacturing Practice (CGMP) standards throughout entire supply chain as a key market differentiator
- 06 Continue to advance the scientific body of evidence substantiating clinical efficacy, economic viability and underlying mechanism of action for our PURION® processed placental tissue platform through additional peer-reviewed publications, including rigorous scientific research and clinical studies

FOOTNOTES:

1. TTM refers to the trailing twelve months ended June 30, 2022
2. Adjusted EBITDA is a non-GAAP measure consisting of GAAP net loss excluding: (i) depreciation, (ii) amortization of intangibles, (iii) interest expense, (iv) income tax provision, (v) costs incurred in connection with Audit Committee Investigation and Restatement, (vi) the effect of the change in revenue recognition on net loss, (vii) share-based compensation, and (viii) impairment of intangible assets. Refer to Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 28, 2022 (the "2021 Annual Report") for defined terms and reconciliation to the nearest GAAP measure.
3. Sen CK. Human Wounds and Its Burden: An Updated Compendium of Estimates. *Adv Wound Care (New Rochelle)*. 2019; 8(2):39-48. doi:10.1089/wound.2019.0946
4. BioMed GPS SmartTrak
5. Tettelbach, WH, Armstrong, DG, Chang, TJ, et al. Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment. *Journal of Wound Care* 2022 31:Sup2, S10-S31.
6. BioMed GPS SmartTrak; GlobalData Tissue Engineered-Skin Sub Data Model Wound Management Year 2020 – retrieved Sept 2021; Management estimates
7. BioMed GPS SmartTrak; 3rd party proprietary assessment; Management estimates
8. GlobalData Tissue Engineered-Skin Sub Data Model Wound Management Year 2020 – retrieved Sept 2021; Management estimates
9. GlobalData: 2020 Orthopedic Devices Knee Reconstruction US (2015-2030)
10. GlobalData: Viscosupplementation Model (HA) US (2015-2030)
11. BioMed GPS SmartTrak; Global Data Tissue Engineered-Skin Sub Data Model Wound Management Year 2020 – retrieved Sept 2021; Global Data Knee Reconstruction Data Model United States 2020; 3rd party proprietary assessment; Management estimates